Abstract
Purpose
IHL-305 is a novel PEGylated liposome containing irinotecan. This study examined the safety profile and pharmacokinetics of IHL-305 and established the maximum tolerated dose and recommended phase II dose (RP2D).
Patients and methods
In a standard 3 + 3 design, IHL-305 was administered IV on day 1 of a 28-day treatment schedule. Subsequently, a 14-day treatment schedule was also explored. Two patient populations were evaluated separately: Patients with at least one wild-type (wt) allele of UGT1A1 (UDP glucoronosyltransferase 1A1) wt/wt or wt/*28 as one group (referred to as UGT1A1 wt group) and patients with UGT1A1*28 homozygous variant (*28/*28) as another group.
Results
Sixty patients were treated: 42 on the 28-day schedule and 18 on the 14-day schedule. Seven patients were homozygous variant (*28/*28). In the UGT1A1 wt group, the MTD and RP2D of IHL-305 was 160 mg/m2 every 28 days and 80 mg/m2 every 14 days. DLTs included nausea, vomiting, diarrhea, and neutropenia. The most common adverse events were nausea (75 %), vomiting (52 %), diarrhea (62 %), anorexia (57 %), and fatigue (57 %). At the MTD for both schedules, IHL-305 administration resulted in a high and prolonged exposure of sum total irinotecan, released irinotecan, and SN-38 in plasma. One partial response was observed in a patient with breast cancer and eight patients had stable disease for >6 months.
Conclusions
IHL-305, a novel preparation of irinotecan encapsulated in liposomes, can be safely given to patients in a repeated fashion on a 4- or 2-week dosing schedule.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Camptosar Package Insert. Pfizer Products Website. http://www.pfizer.com/files/products/uspi_camptosar.pdf
Kuhn JG (1998) Pharmacology of irinotecan. Oncology (Williston Park) 12(8 Suppl 6):39–42
Ma MK, McLeod HL (2003) Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 10:41–49
Marsh S, McLeod HL (2004) Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5:835–843
Hoskins JM, Goldberg RM, Qu P et al (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99:1290–1295
Zamboni WC (2005) Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 11:8230–8234
Slatter JG, Schaaf LJ, Sams JP et al (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C] CPT-11 in cancer patients. Drug Metab Dispos 28(4):423–433
La-Beck NM, Zamboni BA, Gabizon A et al (2012) Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69:43–50
Zamboni WC, Maruca L, Strychor S et al (2010) Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with solid tumors. Clinical Pharmacol Ther 86:519–526
Zamboni WC (2008) Concept and clinical evaluation of nanoparticle and nanosome anticancer agents. Oncologist 13:248–260
Zamboni WC, Yoshino K (2010) Formulation and physiologic factors affecting the pharmacokinetics and pharmacodynamics of liposomal agents. Drug Deliv Syst 25:58–70
Acknowledgments
This work was supported by a grant from Yakult Honsha Co., Ltd to the participating institutions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Infante, J.R., Keedy, V.L., Jones, S.F. et al. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemother Pharmacol 70, 699–705 (2012). https://doi.org/10.1007/s00280-012-1960-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-012-1960-5